-
Remicade®
Remicade® (infliximab) is a biologic infusion therapy used to treat a range of chronic autoimmune and inflammatory conditions by targeting the underlying immune response driving inflammation. For patients living with conditions that cause persistent pain, swelling, fatigue, or organ damage, Remicade can help reduce symptoms, control disease activity, and improve overall quality of life.
How Remicade® Works
Remicade® is a monoclonal antibody that works by blocking tumor necrosis factor-alpha (TNF-α), a protein in the immune system that plays a major role in inflammation.
By inhibiting TNF-α, Remicade helps relieve symptoms related to inflammation, promote healing of affected tissues, and slow disease progression. Many patients experience improved symptom control, reduced flare frequency, and better daily function with ongoing therapy.
Key Details
Important Information
| Category | Details |
|---|---|
| Conditions It Treats | Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis |
| Manufacturer | Janssen Biotech, Inc. |
| Administered by | Infusion |
| Frequency | 6–8 weeks |
| Length of Infusion | ~2 hours |
| FDA Approval(s) | Crohn’s Disease: Approved August 24, 1998 Rheumatoid Arthritis: Approved November 4, 1999 Ulcerative Colitis: Approved September 24, 2005 |